What Prascend chevaux Treats: Main Uses and Benefits

Prascend is commonly used for the management of clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) in horses, a chronic disease often referred to as Equine Cushing’s Disease. The medication is relevant for easing the symptomatic manifestations of this condition. It is a life-long therapeutic approach generally used in the aged and geriatric equine population to support endocrine management.

This medication is generally used in conditions marked by the progressive symptoms of the underlying endocrine disorder, and it helps address symptom clusters that may become intense or disruptive, including hypertrichosis (abnormally long, unseasonal coat) and chronic muscle wasting. This therapy is commonly used to help with the management of the disease state and may assist with maintaining functional stability over time.

Prascend is relevant in contexts involving heightened systemic burden, such as the metabolic disturbances associated with PPID, and it may assist with managing the risk of associated laminitis. It is used for managing symptoms related to systemic imbalance, such as excessive drinking and urination (polydipsia and polyuria), and is relevant for easing the infectious manifestations associated with immunosuppression. The medication offers symptomatic relief that helps patients cope more steadily with symptom fluctuations and helps ease the overall burden of functional impairments.

---

Quick Fact: Support for Integumentary Symptoms Prascend is relevant for managing coat abnormalities, particularly hypertrichosis (abnormally long hair coat) and issues with seasonal shedding that are characteristic of PPID.

Regulatory References

1. HPRA Product Information

Who can and cannot use Prascend chevaux? — Official Eligibility Information

Prascend (pergolide mesylate) is strictly for use in horses and is available by prescription from a licensed veterinarian. Eligibility for this medicine is defined by official regulatory documents through absolute contraindications and specific population restrictions.

Contraindicated Populations

The medicine must not be used in the following groups:

Classification	Population/Condition
Absolute Contraindication	Horses with known hypersensitivity to pergolide mesylate, other ergot derivatives, or any excipients.
Age Restriction	Horses less than 2 years of age.

Restricted or Not Recommended Populations

Use is highly restricted or not recommended for certain physiological states:

• Food-Producing Status: Use is not authorized for horses intended for human consumption or for mares producing milk for human consumption. The horse must be officially declared as not intended for food production.
• Lactating Mares: Use is not recommended as the safety of the product has not been established in this group.
• Pregnant Mares: Use is permissible only after a thorough benefit/risk assessment is conducted by the responsible veterinarian, as safety has not been demonstrated in pregnant mares.

Overall Eligibility Profile

Regulatory documents limit the use of Prascend to non-food-producing horses over two years of age who do not have a known allergy to the drug or its class. Special veterinary consultation is required before use in pregnant mares, and use in lactating mares is generally not recommended.

Interactions with other medicines and products

The official regulatory profile for Prascend (pergolide mesylate) identifies two main categories of interactions, primarily related to functional opposition and the drug’s binding properties.

Pharmacodynamic Interactions

Prascend acts as a dopamine receptor agonist. Co-administration with medicinal products that block dopamine receptors (Dopamine Antagonists) may diminish the intended therapeutic effect of Prascend. Regulatory information advises that co-administration with these substances should be avoided.

• Dopamine Antagonist Examples: This restriction applies to neuroleptics, specifically Phenothiazines (such as Acepromazine), Metoclopramide, and Domperidone.

Potential for Exposure Alteration

Pergolide mesylate is highly bound to plasma proteins, with approximately 90% binding observed. This physicochemical property establishes a potential for competitive displacement. Therefore, caution is advised if the product is co-administered with other medicinal products known to significantly affect plasma protein binding, as this could alter the exposure of either drug.

Other Interaction Considerations

The official regulatory documentation does not contain specific restrictions or warnings regarding interactions with food (feed), alcohol, herbal products, or supplements. Additionally, the labeling does not explicitly document or categorize interactions based on Cytochrome P450 (CYP) enzyme systems or specific drug transporter mechanisms.

Dopamine Receptor Agonism

The medication's active ingredient functions as a highly specific agonist (activator) for Dopamine D2 receptors. It selectively targets these receptors, which are primarily expressed on the hormone-producing cells (melanotropes) within the pars intermedia of the pituitary gland. By binding to the D2 receptors, the drug mimics the inhibitory signal of natural dopamine, thereby initiating a direct suppression of the proliferative and secretory activity in these cells.

---

Regulation of Pituitary Hormone Secretion

This mechanism involves modulating the neuroendocrine pathway that controls hormone release. The D2 receptor activation reduces the excessive synthesis and subsequent release of various hormones, including the precursor to adrenocorticotropic hormone (ACTH), into the systemic circulation. This restored inhibitory control on the pars intermedia cells contributes to the modulation of systemic hormone concentrations, resulting in modulation of endocrine regulation across peripheral systems.

The administration of Prascend (pergolide mesylate) follows a defined protocol centered on oral, weight-based dosing and titration. The medication is supplied as a 1 mg scored tablet intended for once-daily oral use in the targeted equine population.

Official Administration Guidelines

Feature	Official Usage Instruction
Route & Frequency	Administered by the oral route, once daily (q.d.).
Dosing Schedule	Initial dose is 2 mcg/kg body weight. Dosage is adjusted in 0.5 mg increments every 2 to 6 weeks based on patient response, with the tablet provided to the nearest half-tablet.
Preparation	The tablet may be administered directly, mixed with feed, or dissolved in water or a sweetener, which must then be administered immediately via a syringe.
Duration of Use	Treatment for the underlying endocrine condition is typically considered to be life-long.

Special Procedural Conditions

The tablets are scored to ensure precise half-tablet increments for dosing; however, the tablets must not be crushed due to the potential for occupational human exposure to pergolide mesylate. The initial phase of treatment requires periodic endocrine testing and clinical assessment to determine the appropriate adjustments, establishing a defined titration period. This structured approach ensures the continuous, controlled delivery of the active substance within official parameters.

Research Evidence: Overview of Studies for Prascend chevaux

---

Evidence for Pituitary Pars Intermedia Dysfunction (PPID)

Research concerning Prascend and PPID has primarily relied on regulatory field studies. These studies often utilized an open-label design with historical controls, meaning comparisons were observed against previously established disease patterns rather than a contemporary control group. Studies monitored key outcomes related to systemic or functional imbalance. Researchers measured shifts in specific endocrine biomarkers, such as levels of Adrenocorticotropic hormone (ACTH), and tracked changes in visible clinical signs like the abnormal hair coat (hypertrichosis), muscle wasting, and patterns of excessive water intake and urination (polydipsia and polyuria).

Research has explored the evidence structure, noting that while regulatory studies provided data for a determination of protocol findings, the primary evidence relies on a design that is not a blinded, randomized comparison. Data on the active substance reported low and variable plasma concentrations and a short half-life in the target species. This research contributes to the broader evidence landscape but does not determine whether an individual will respond similarly.

---

Structure of Study Design and Evidence Quality

Attribute	Description
Evidence Level	Moderate (Due to the reliance on open-label field studies)
Primary Study Design	Open-label field studies with historical controls
Key Limitation	Comparative evidence against a contemporary control group is lacking in the primary data

The overall evidence level is generally considered moderate. The main studies supporting regulatory approval were open-label field studies. This type of research design provides context but not individual predictions. The methodological choice of using historical controls means that the findings are primarily descriptive of group patterns, not personal outcomes.

---

Long-Term Data and Follow-up Durations

The primary effectiveness evaluations monitored responses over defined time intervals, with core outcomes assessed up to six months (180 days). This follow-up duration was limited when considering the typical long-term nature of the condition. Consequently, long-term effects are not fully established by the existing core research base. The long-term consistency of initial changes observed in clinical signs and biomarkers over years is not well characterized by the original regulatory evidence. Follow-up durations were limited to six months in the primary evaluation studies.

Key Studies & References

1. Corrected Freedom of Information Summary: New Animal Drug Application NADA 141-331 - PRASCEND Tablets (Pergolide Mesylate) Horse
2. Summary of Product Characteristics (SPC) - Prascend 1 mg Tablets for Horses (European Regulatory Information)
3. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction

Common questions about Prascend chevaux (FAQ)

---

Q: What is the maximum or target stable dose of Prascend for a horse?

Official product information states that the starting dose for Prascend is based on the horse’s body weight. Regulatory documents indicate that the final maintenance dose is determined by the veterinarian based on the horse’s clinical and endocrine response over time. The goal of treatment is to find the lowest effective dose for the individual animal.

---

Q: Can Prascend be used in pregnant or breeding mares?

Regulatory documents indicate that the safety of Prascend has not been evaluated in pregnant, lactating, or breeding horses. The drug’s mechanism of action suggests it may interfere with normal reproductive functions. Therefore, use in pregnant mares requires a thorough benefit/risk assessment by the responsible veterinarian, as safety has not been demonstrated.

---

Q: What other medications should not be given with Prascend?

Regulatory information indicates that co-administration with medicines known as dopamine antagonists should be avoided, as this may diminish the therapeutic effect of Prascend. Examples of these medications include specific neuroleptics, phenothiazines (such as Acepromazine), Metoclopramide, and Domperidone. Caution is also noted with other medicines that significantly affect how drugs bind to blood proteins.

---

Q: How is the dose of Prascend determined and adjusted?

The initial dose is calculated by the veterinarian based on the horse's body weight. Regulatory guidelines state that the dosage is subsequently adjusted in increments based on the animal’s clinical response and periodic endocrine testing, typically over intervals of two to six weeks, until a stable effect is reached.

---

Q: What happens if a dose of Prascend is accidentally missed?

Regulatory documents advise that if a dose is missed, the next dose should be given at the regularly scheduled time, and a double dose should not be administered. Studies have observed that the concentrations of the hormone (ACTH) that the drug is designed to control may begin to rise within 48 hours after treatment is interrupted.

---

Q: How long does it typically take for a horse's ACTH levels to drop after starting Prascend?

Studies supporting regulatory approval reported that changes in clinical signs (like hair coat changes) were observed within three months of starting treatment, with assessments continuing up to six months. Diagnostic testing for dose adjustments is typically performed at four-to-six-week intervals.

---

Q: Is it safe for a person to handle or touch the Prascend tablets without gloves?

Product labeling states that the tablets should be handled with care to minimize human exposure. It is specifically stated that pregnant or lactating women must wear gloves during administration. Hands should be washed after handling, as accidental ingestion or exposure to this medication, an ergot derivative, may cause side effects in humans.

---

Q: Does Prascend need to be given with food, or can it be given alone?

According to the official administration guidelines, Prascend can be administered directly to the horse, or it may be mixed with feed or dissolved in a small amount of water or sweetener for immediate administration by syringe. There is no explicit regulatory requirement that the medication must be given alongside a meal.

Storage and Disposal Requirements

Prascend tablets must be stored at or below 25°C (77°F) and should be protected from direct sunlight and extremes of temperature. The product must be kept in its original blister packaging inside the outer carton to maintain stability. The authorized shelf-life is 3 years as packaged for sale.

Area	Constraint
Child/Animal Safety	Keep out of the sight and reach of children, dogs, and cats.
Handling	Tablets should not be crushed; pregnant or lactating women must wear gloves during administration.
Disposal	Do not dispose of via wastewater or household waste; follow local regulatory requirements for disposal of unused product.

Storage must be separate from human medicines, food, drink, and animal feedingstuffs.